Franklin Parlapiano Turner & Welch LLC Acquires Shares of 23,776 Stryker Corporation $SYK

Franklin Parlapiano Turner & Welch LLC acquired a new stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 23,776 shares of the medical technology company’s stock, valued at approximately $7,486,000. Stryker accounts for about 1.7% of Franklin Parlapiano Turner & Welch LLC’s investment portfolio, making the stock its 19th largest position.

A number of other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its position in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker during the second quarter worth about $205,000. Marshall Wace LLP lifted its stake in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new position in Stryker in the second quarter valued at about $219,000. Finally, HUB Investment Partners LLC purchased a new position in Stryker in the second quarter valued at about $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.1%

NYSE:SYK opened at $338.85 on Monday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $320.11 and its two-hundred day moving average is $333.92. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a market cap of $129.97 billion, a PE ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the firm earned $3.13 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. 4.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SYK shares. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Barclays reduced their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Truist Financial raised their price target on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. dropped their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Needham & Company LLC cut their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.